Effect of Raw Versus Roasted Fenugreek Seed Powder in Reducing Blood Glucose Levels in Type 2 Diabetic Patients

NCT ID: NCT05550870

Last Updated: 2023-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-24

Study Completion Date

2022-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetes is a metabolic disorder that causes high glucose levels in the blood and leads to various complications with time such as Retinopathy, neuropathy, and nephropathy, and puts a lot of burden on the health of a person as well as economy of country. Fenugreek is being used for decades in the treatment of various diseases and disorders including diabetes. With the advancement of medical nutrition therapy and processing techniques, it is being used in roasted or cooked form. But previous studies indicate that processing like roasting decrease the fiber content of fenugreek seed and this fiber mainly galactomannan is responsible for reducing hyperglycemia. Another study tells us that in raw form the glycemic index is lowered as compared to roasted or other forms.According to another study the antioxidant activity is increased in roasted form as compared form. So in this study, a clinical trial will be done on two groups of 15 type 2 diabetic patients each that have neither other complications nor on insulin therapy. These total 30 patients Height, Weight, BMI, Fasting and Random Blood sugars, HbA1c, and lipid profile will be checked before the study and after 3 months of a clinical trial. Group 1 will be given Raw fenugreek seed powder and group 2 will be given Roasted fenugreek seed powder 7.5 grams twice a day.The study will be single blinded.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetes mellitus is a metabolic disorder that is marked by high glucose levels in the blood because of insulin resistance or inability of the pancreas to make enough insulin for proper working of carbohydrate metabolism. It is easily obvious from the literature that its prevalence is increasing day by day and in future it seems to rise more. Its complications lead to more problematic situation for the health of diabetic person itself and the economy with each day. Its management includes diet, physical activity and medications. As a dietary component different spices are being used for years like cinnamon and fenugreek. Many people use fenugreek in various forms like its incorporation in chapatti, Indian dish Dosa and others but the form of fenugreek is still un known based on the effectiveness that either it will be more beneficial in cooked form like roasting or in raw form for reducing hyperglycemia, because many people take it in roasted form as it decreases its bitterness. As fenugreek is cheap it is of major concern of many diabetic patients for diabetes management.

This study is aimed to determine the effect of Raw versus Roasted Fenugreek seed powder in reducing the blood glucose levels in Type 2 Diabetic patients which will be evidenced by Fasting Blood Glucose, Random Blood Glucose and HbA1c

OBJECTIVE of the study is:

1\. To explore the potential of Raw and Roasted fenugreek against biomarkers of Type 2 Diabetes in Diabetic Patients.

The methodology of the study comprises of three different phases. Phase 1: Processing of fenugreek Phase 2: Assessment of diabetic patients regards to inclusion and exclusion criteria and groups assignment along with fenugreek sachets Phase 3: Assessment of biochemical tests and anthropometric measurements at the end of the study

Phase 1: Processing of fenugreek Fenugreek will be brought form the local market and will be cleaned for the stones and straws. Fenugreek seeds will be roasted in oven at approximately 130 ± 5 °C for 7 minutes with stirring at regular intervals with laddle so that it will properly and uniformly roasted and it will turn to slight brownish colour along with peculiar aroma. Raw and Roasted fenugreek seeds will be grounded in grinder to get uniform sized flour. Flours will be collected and stored in air tight food grade containers separately for further use at ambient temperature.

Phase 2: Assessment of diabetic patients regards to inclusion and exclusion criteria and groups assignment along with fenugreek sachets

Subjects:

For the study the diabetic patients will be gathered in the diabetic camp at Lahore where their anthropometric and blood sample collection will be done. The participants will be divided in to two groups Group 1 and group 2 with equal participants of 15 in each group. Total 30 patients of Type 2 Diabetes will be selected for this clinical trial .The inclusion criteria include age ranging from 30-50 years old male and female type 2 diabetic patients from Lahore with informed consent and Patients with Diabetes diagnosed from past 5- 15 years. The exclusion criteria consist of: Anyone suffering from any other chronic disease like Cardiac, Pulmonary and Chronic Renal Disease and patients other than inclusion criteria, any diabetic patients on Insulin therapy and Pregnant and Breastfeeding women. Any one suffering from chickpeas, peanut or coriander allergy. Height, weight and BMI of all patients will be checked as anthropometric measures. Patients BMI will be classified according to WHO criteria.

Whereas BMI =Weight in kg/Height in meter squares. Random, fasting blood sugars will be tested along with HbA1c and Lipid profile. The participants will be divided in to two groups one with Raw fenugreek and second with Roasted one. The duration of the study will be 3 months.

Experimental design:

Group 1 will be given Raw Fenugreek in Ziploc sachets of 7.5 grams (2 sachets for a day equals to 15 grams) for every 2 weeks, ultimately for period of 3 months. Bimonthly their Fasting and Random Blood sugar will be checked also. Participants will be told to take 1 sachet before breakfast and one before dinner. Similarly Group 2 will be given the Roasted fenugreek in the same manner as that of group 1.The participants will be allowed to take their regular oral medications like metformin for diabetes. There will be a gap of 1-2 hours between oral medications (oral hypoglycemic agents) and fenugreek intake as its fiber becomes mucilaginous and can interfere with the drug activity.

Biochemical testing:

Anthropometric measurements such as height weight and BMI will be checked at baseline, and after three months. Besides the anthropometry, the study participant's Fasting and Random Blood glucose levels will be checked before, after every two weeks and after completion of the study. In addition after every 2 weeks through Glucometer by using finger prick method. Before, and at the end of the study HbA1c will be checked also. Patients Blood Lipid Profile will also be checked before and after the study.

Phase 3: Assessment of biochemical tests and anthropometric measurements at the end of the study At the end of the study, HbA1c along with fasting and Random Blood Sugars will be tested so that effectiveness of both groups to their baselines can be compared after the study. Lipid profile will also be monitored and compared to the base lines. Their height, weight and BMI will also be monitored at the end of the study and will be compared to the baselines.

Statistical analysis:

Statistical Package for Social Science software (version 22) will be used for the analysis of data. Independent t test will be applied to check the differences between group 1 and group 2 at baseline. Paired t test will be used to check the differences between baselines and final results after treatment within a group. One way ANOVA will also be used.The level of significance will be \<0.05

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

There are two groups, Group 1 will be given raw fenugreek and group 2 will be given roasted fenugreek. Results will be compared to baselines.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
It is a single-blind clinical trial, in which patients know that fenugreek is being given to them but which form either raw or roasted is unknown to them

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Group 1 will be given Raw Fenugreek seed powder. The dose will be 7.5grams two times a day i.e, before breakfast and before dinner for the period of three months.

Group Type EXPERIMENTAL

Raw fenugreek seed powder

Intervention Type DIETARY_SUPPLEMENT

It will be given to group 1

Group 2

Group 2 will be given Roasted Fenugreek seed powder, 7.5 grams twice a day before breakfast and dinner for the period of three months.Total number of arms will be 2.

Group Type EXPERIMENTAL

Roasted fenugreek seed powder

Intervention Type DIETARY_SUPPLEMENT

It will be given to group 2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Raw fenugreek seed powder

It will be given to group 1

Intervention Type DIETARY_SUPPLEMENT

Roasted fenugreek seed powder

It will be given to group 2

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- 30-50 years of Type 2 Diabetic patients with past 5-15 years of diabetes Type 2

Exclusion Criteria

* Any patient on insulin therapy
* Patients with other chronic diseases like Cardiac, Renal, or Pulmonary diseases.
* Pregnant and Lactating mothers
* Anyone with peanut or coriander allergy or Allergy to Fabeace Family
Minimum Eligible Age

30 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Veterinary and Animal Sciences, Lahore - Pakistan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sanaullah Iqbal

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Veterinary and Animal Sciences, Paksitan

Lahore, Punjab Province, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

References

Explore related publications, articles, or registry entries linked to this study.

Abdelwahab NS, Morsi A, Ahmed YM, Hassan HM, AboulMagd AM. Ecological HPLC method for analyzing an antidiabetic drug in real rat plasma samples and studying the effects of concurrently administered fenugreek extract on its pharmacokinetics. RSC Adv. 2021 Jan 25;11(8):4740-4750. doi: 10.1039/d0ra08836f. eCollection 2021 Jan 21.

Reference Type BACKGROUND
PMID: 35424379 (View on PubMed)

Ahmad A, Amir RM, Ameer K, Ali SW, Siddique F, Hayat I, Ahmad Z, Faiz F. 2020. Ameliorative effects of fenugreek (Trigonella foenum-graecum) seed on type 2 diabetes. Food Sci. Technol.(AHEAD).

Reference Type BACKGROUND

Ahmad H, Kashif S, Afreen A, Safdar M, Ahmed Z. 2021. Comparative effect of Fenugreek and Cinnamon on management of newly diagnosed cases of Type-2 Diabetes Mellitus. Food Sci. Technol.

Reference Type BACKGROUND

Alshali KZ. 2020. Review of herb supplement use in type 2 diabetes. Archives of Pharmacy Practice. 11(2).

Reference Type BACKGROUND

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010 Jan;33 Suppl 1(Suppl 1):S62-9. doi: 10.2337/dc10-S062. No abstract available.

Reference Type BACKGROUND
PMID: 20042775 (View on PubMed)

Ansari R, Ansari S. 2011. Effectiveness of fenugreek for lowering hemoglobin (HbA1c) in patients with self-management of type 2 diabetes: a randomized, controlled trial. Medical Complications of Type. 2: 393-412.

Reference Type BACKGROUND

Baset ME, Ali TI, Elshamy H, El Sadek AM, Sami DG, Badawy MT, Abou-Zekry SS, Heiba HH, Saadeldin MK, Abdellatif A. 2020. Anti-diabetic effects of fenugreek (Trigonella foenum-graecum): A comparison between oral and intraperitoneal administration - an animal study. Int J Funct Nutr. 1(1): 2.

Reference Type BACKGROUND

Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017 Jun 3;389(10085):2239-2251. doi: 10.1016/S0140-6736(17)30058-2. Epub 2017 Feb 10.

Reference Type BACKGROUND
PMID: 28190580 (View on PubMed)

Das S, Dhananjaya BL, Desiraju S. 2018. Trigonella foenum-graceum (fenugreek) for Management of Diabetes. Int. j. biochem. res. 14(3): 1-10.

Reference Type BACKGROUND

Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. Diabetol Metab Syndr. 2017 Jul 26;9:59. doi: 10.1186/s13098-017-0254-9. eCollection 2017.

Reference Type BACKGROUND
PMID: 28770011 (View on PubMed)

Haber SL, Keonavong J. Fenugreek use in patients with diabetes mellitus. Am J Health Syst Pharm. 2013 Jul 15;70(14):1196, 1198, 1200, 1202-3. doi: 10.2146/ajhp120523. No abstract available.

Reference Type BACKGROUND
PMID: 23820455 (View on PubMed)

Hassani SS, Fallahi Arezodar F, Esmaeili SS, Gholami-Fesharaki M. Effect of Fenugreek Use on Fasting Blood Glucose, Glycosylated Hemoglobin, Body Mass Index, Waist Circumference, Blood Pressure and Quality of Life in Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trials. Galen Med J. 2019 Mar 30;8:e1432. doi: 10.31661/gmj.v8i0.1432. eCollection 2019.

Reference Type BACKGROUND
PMID: 34466512 (View on PubMed)

Jiang JX, Zhu LW, Zhang WM, Sun RC. 2007. Characterization of Galactomannan Gum from Fenugreek (Trigonella foenum-graecum) Seeds and Its Rheological Properties. Int. J. Polym. 56(12): 1145-1154.

Reference Type BACKGROUND

Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015 Jun 25;6(6):850-67. doi: 10.4239/wjd.v6.i6.850.

Reference Type BACKGROUND
PMID: 26131326 (View on PubMed)

Khursheed R, Singh SK, Wadhwa S, Kapoor B, Gulati M, Kumar R, Ramanunny AK, Awasthi A, Dua K. Treatment strategies against diabetes: Success so far and challenges ahead. Eur J Pharmacol. 2019 Nov 5;862:172625. doi: 10.1016/j.ejphar.2019.172625. Epub 2019 Aug 23.

Reference Type BACKGROUND
PMID: 31449807 (View on PubMed)

Kumar K, Kumar S, Datta A, Bandyopadhyay A. 2015. Effect of fenugreek seeds on glycemia and dyslipidemia in patients with type 2 diabetes mellitus. Int. j. health med. 4(7): 997-1000.

Reference Type BACKGROUND

Majeed M, Majeed S, Nagabhushanam K, Arumugam S, Natarajan S, Beede K, Ali F. Galactomannan from Trigonella foenum-graecum L. seed: Prebiotic application and its fermentation by the probiotic Bacillus coagulans strain MTCC 5856. Food Sci Nutr. 2018 Feb 20;6(3):666-673. doi: 10.1002/fsn3.606. eCollection 2018 May.

Reference Type BACKGROUND
PMID: 29876118 (View on PubMed)

Pandey H, Awasthi P. Effect of processing techniques on nutritional composition and antioxidant activity of fenugreek (Trigonella foenum-graecum) seed flour. J Food Sci Technol. 2015 Feb;52(2):1054-60. doi: 10.1007/s13197-013-1057-0. Epub 2013 Jun 12.

Reference Type BACKGROUND
PMID: 25694718 (View on PubMed)

Pradeep SR, Srinivasan K. Amelioration of hyperglycemia and associated metabolic abnormalities by a combination of fenugreek (Trigonella foenum-graecum) seeds and onion (Allium cepa) in experimental diabetes. J Basic Clin Physiol Pharmacol. 2017 Sep 26;28(5):493-505. doi: 10.1515/jbcpp-2015-0140.

Reference Type BACKGROUND
PMID: 28599386 (View on PubMed)

Ranade M, Mudgalkar N. A simple dietary addition of fenugreek seed leads to the reduction in blood glucose levels: A parallel group, randomized single-blind trial. Ayu. 2017 Jan-Jun;38(1-2):24-27. doi: 10.4103/ayu.AYU_209_15.

Reference Type BACKGROUND
PMID: 29861588 (View on PubMed)

Sanlier N, Gencer F. 2020. Role of spices in the treatment of diabetes mellitus: A minireview. Trends Food Sci Technol . 99: 441-449.

Reference Type BACKGROUND

Sarwar S, Hanif MA, Ayub MA, Boakye YD, Agyare C. 2020. Fenugreek. In. Medicinal Plants of South Asia. Elsevier. p. 257-271.

Reference Type BACKGROUND

Sharma R. 1986. Effect of fenugreek seeds and leaves on blood glucose and serum insulin responses in human subjects. Nutr Res 6(12): 1353-1364.

Reference Type BACKGROUND

Srinivasan K. 2019. Chapter 3.15 - Fenugreek (Trigonella foenum-graecum L.) Seeds Used as Functional Food Supplements to Derive Diverse Health Benefits. In: Nabavi SM, Silva AS, editors. Nonvitamin and Nonmineral Nutritional Supplements. Academic Press. p. 217-221.

Reference Type BACKGROUND

Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: Current situation and perspectives. Eur J Prev Cardiol. 2019 Dec;26(2_suppl):7-14. doi: 10.1177/2047487319881021.

Reference Type BACKGROUND
PMID: 31766915 (View on PubMed)

Suchitra M, Parthasarathy S. 2015. Effect of administration of fenugreek seeds on HbA1C levels in uncontrolled diabetes mellitus-a randomized controlled trial. Int J Pharm Tech Res. 8(2): 180-182.

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Raw versus Roasted Fenugreek

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Curcumin for Type 2 Diabetic Patients
NCT01052597 UNKNOWN PHASE4